Cellceutix progress 2011 Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013 Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin June 17 2013 Stability test for Purisol tablets September 15 2013 Aquires Polymedix October 2 2013 IND new Psoriasis drug Prurisol
2014 February 24 2014 Brilacidin ophthalmic and otitis formulations started February 25 2014 First patients 2b ABSSI enrolled March 19 2014 Seventh cohort for Kevetrin initiated March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort June 16 2014 Eight cohort entering for Kevetrin July 18 2014 Breakthrough formulation for Brilacidin Aug 07 2014 Prurisol primary end point met Sept 19 2014 IND filed Brilacidin OM Oct 23 2014 IND Brilacidin OM becomes effective Oct 31 2014 Positive Top Line data regarding Brilicidin phII b December 10 2014 Brilacidin QIPD designation December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2 Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.